PTH and chronic kidney disease: The authors showed that after 26 weeks, ERC therapy resulted in a progressively better pattern of circulating 1,25(OH)2D levels, plasma PTH, and serum bone turnover markers, independent of CKD stage and without adverse repercussions on safety parameters.